Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib

References

• World Cancer Research Fund International. Breast cancer statistics. Available from: https://www.wcrf.org/cancer-trends/breast-cancer-statistics/. Accessed July 25, 2023.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). doi:10.1093/jnci/dju055
   PubMedGoogle Scholar
• Sbitti Y, Slimani K, Debbagh A, et al. Visceral crisis means short survival among patients with luminal A metastatic breast cancer: a retrospective cohort study. World J Oncol. 2017;8(4):105–109. doi:10.14740/wjon1043w
   PubMedGoogle Scholar
• Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316. doi:10.1056/NEJMoa1903765
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi:10.1200/JCO.2017.75.6155
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi:10.1056/NEJMoa1607303
   PubMed Web of Science ®Google Scholar
• Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–124. doi:10.1001/jamaoncol.2019.4782
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi:10.1056/NEJMoa1609709
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364–1382. doi:10.5858/arpa.2018-0902-SA
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 2003;63(7):1445–1448.
   PubMed Web of Science ®Google Scholar
• Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. Breast Cancer Res Treat. 2015;151(2):357–364. doi:10.1007/s10549-015-3407-2
   PubMed Web of Science ®Google Scholar
• Won HS, Ahn J, Kim Y, et al. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res. 2022;24(1):22. doi:10.1186/s13058-022-01519-x
   PubMed Web of Science ®Google Scholar
• Eggemann H, Ignatov T, Burger E, et al. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer. Endocr Relat Cancer. 2015;22(5):725–733. doi:10.1530/ERC-15-0335
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi:10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers. 2021;13(11):2824. doi:10.3390/cancers13112824
   PubMed Web of Science ®Google Scholar
• Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–1962. doi:10.1200/JCO.19.02488
   PubMed Web of Science ®Google Scholar
• Kurozumi S, Padilla M, Kurosumi M, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99–111. doi:10.1007/s10549-016-3856-2
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Cecchini RS, Geyer CE, et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol. 2020;38(5):444–453. doi:10.1200/JCO.19.01455
   PubMed Web of Science ®Google Scholar
• Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull. 2019;67(3):173–185. doi:10.1248/cpb.c18-00744
   PubMed Web of Science ®Google Scholar
• Takegawa N, Tsurutani J, Kawakami H, et al. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer. 2019;145(12):3414–3424. doi:10.1002/ijc.32408
   PubMed Web of Science ®Google Scholar
• Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a Phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–1135. doi:10.1016/S1470-2045(19)30328-6
   PubMed Web of Science ®Google Scholar
• Bao KKH, Sutanto L, Tse SSW, Man Cheung K, Chan JCH. The association of ERBB2-low expression with the efficacy of cyclin-dependent kinase 4/6 inhibitor in hormone receptor-positive, ERBB2-negative metastatic breast cancer. JAMA Netw Open. 2021;4(11):e2133132. doi:10.1001/jamanetworkopen.2021.33132
   PubMed Web of Science ®Google Scholar
• Douganiotis G, Kesisis G, Lalla E, Korantzis I, Boukovinas I, Papazisis K. Prognostic significance of low HER2 expression in patients with metastatic hormone receptor-positive breast cancer treated with first line CDK4/6 inhibitors: a Greek multicenter real-world data analysis. Cancer Diagn Progn. 2022;2(5):585–591. doi:10.21873/cdp.10146
   PubMedGoogle Scholar
• Carlino F, Diana A, Ventriglia A, et al. HER2-low status does not affect survival outcomes of patients with Metastatic Breast Cancer (MBC) undergoing first-line treatment with endocrine therapy plus palbociclib: results of a multicenter, retrospective cohort study. Cancers. 2022;14(20):4981. doi:10.3390/cancers14204981
   PubMed Web of Science ®Google Scholar
• Shao Y, Luo Z, Yu Y, et al. HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: a real-world study. Front Endocrinol. 2022;13:1000704. doi:10.3389/fendo.2022.1000704
   PubMed Web of Science ®Google Scholar
• Robbins CJ, Fernandez AI, Han G, et al. Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry. Mod Pathol. 2023;36(1):100032. doi:10.1016/j.modpat.2022.100032
   PubMed Web of Science ®Google Scholar
• Lambein K, Van Bockstal M, Vandemaele L, et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol. 2013;140(4):561–566. doi:10.1309/AJCP4A7KTAYHZSOE
   PubMed Web of Science ®Google Scholar
• Casterá C, Bernet L. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH. Ann Diagn Pathol. 2020;45:151451. doi:10.1016/j.anndiagpath.2019.151451
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Peddi PF, Tetef ML, et al. TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. J Clin Oncol. 2021;39(15_suppl):TPS603–TPS603. doi:10.1200/JCO.2021.39.15_suppl.TPS603
   Web of Science ®Google Scholar